Is Trulicity or Ozempic approved for weight loss?

Neither. Both labels cover type 2 diabetes, with cardiovascular indications alongside. Semaglutide holds a separate weight management approval under the name Wegovy; dulaglutide holds no weight approval under any name.

Which one is stronger?

The labels do not compare them, and their doses cannot be compared either: 4.5 mg of dulaglutide and 2 mg of semaglutide are amounts of different substances. This page does not rank them.

What happens if a weekly dose is missed?

The two labels answer differently. Trulicity may be given as soon as possible provided at least 72 hours remain until the next scheduled dose. Ozempic may be given within 5 days of the missed dose. After those windows both labels direct the patient to skip and resume the usual schedule.

Is there a generic version of either?

Not for dulaglutide: it is a biologic, so copies would be biosimilars rather than generics, and none is approved. Semaglutide is a small molecule approved under a new drug application, but no approved generic semaglutide exists in the United States either.

Weight lossTwo labels compared

Trulicity vs Ozempic

Trulicity and Ozempic are the two best known weekly injections in the GLP-1 class, and they contain different molecules. Both labels cover type 2 diabetes. Neither covers weight management, which is the use most people are asking about when they compare them.

Trulicity

Ingredient: Dulaglutide
Approved for: Type 2 diabetes, and cardiovascular risk in heart diseasenot weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $487.63 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

Eli Lilly and Company. Label version 62, effective 16 June 2026.

Ozempic injection

Ingredient: Semaglutide
Approved for: Type 2 diabetes, with cardiovascular and kidney indicationsnot weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $331.97 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

A-S Medication Solutions. Label version 1, effective 30 July 2026.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	TrulicityDulaglutide	Ozempic injectionSemaglutide
Active ingredient	TrulicityDulaglutideGLP-1 receptor agonist	Ozempic injectionSemaglutideGLP-1 receptor agonist
Approved for	TrulicityType 2 diabetes, and cardiovascular risk in heart disease	Ozempic injectionType 2 diabetes, with cardiovascular and kidney indications
Supplysame in both	TrulicityPrescription	Ozempic injectionPrescription
What pharmacies payAcquisition cost, not retail	Trulicity$487.63 per milliliter, brand	Ozempic injection$331.97 per milliliter, brand
Boxed warningsame in both	TrulicityWARNING: RISK OF THYROID C-CELL TUMORS	Ozempic injectionWARNING: RISK OF THYROID C-CELL TUMORS
What the FDA approved it for	Trulicity To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.	Ozempic injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Forms and strengths	Trulicity Injection: TRULICITY is a clear and colorless solution available as: 0.75 mg/0.5 mL solution in a single-dose pen 1.5 mg/0.5 mL solution in a single-dose pen 3 mg/0.5 mL solution in a single-dose pen 4.5 mg/0.5 mL solution in a single-dose pen Injection: 0.75 mg/0.5 mL solution in a single-dose pen Injection: 1.5 mg/0.5 mL solution in a single-dose pen Injection: 3 mg/0.5 mL solution in a single-dose pen Injection: 4.5 mg/0.5 mL solution in a single-dose pen	Ozempic injection Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe
How the label says it is taken	Trulicity Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control. If additional glycemic control is needed, increase dosage in 1.5 mg increments after at least 4 weeks on the current dosage. Maximum recommended dosage is 4.5 mg injected subcutaneously once weekly. Pediatric Dosage If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. Important Administration Instructions Administer once weekly at any time of day with or without food. Inject subcutaneously in the abdomen, thigh, or upper arm.	Ozempic injection Administer once weekly at any time of day, with or without meals. Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage. If a dose is missed, administer within 5 days of missed dose. Inject subcutaneously in the abdomen, thigh, or upper arm. Important Administration Instructions
Most common adverse reactions	Trulicity Most common adverse reactions (incidence ≥5%) are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.	Ozempic injection most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.
Warnings and precautions	Trulicity Thyroid C-cell Tumors: See Boxed Warning. Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including TRULICITY. Discontinue if pancreatitis is suspected. Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) have occurred. Discontinue TRULICITY and promptly seek medical advice. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.	Ozempic injection Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. Never share an OZEMPIC pen between patients, even if the needle is changed. Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. OZEMPIC is not recommended in patients with severe gastroparesis. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if suspected and promptly seek medical advice. Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.
Contraindications	Trulicity TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY. Patients with a serious hypersensitivity reaction to dulaglutide or any of the product components.	Ozempic injection Personal or family history of MTC or in patients with MEN 2. Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC.
Drug interactions	Trulicity Oral Medications: Delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications.	Ozempic injection Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.
Label version	Trulicity16 June 2026	Ozempic injection30 July 2026

02Written by us

Neither label approves weight loss, and the reason differs

The Trulicity label covers glycemic control in type 2 diabetes in adults and pediatric patients aged 10 and older, and reducing the risk of major adverse cardiovascular events in adults who have type 2 diabetes with established cardiovascular disease or multiple risk factors. The Ozempic label covers glycemic control in adults, the same cardiovascular indication in adults with established disease, and a third indication for kidney outcomes in chronic kidney disease.

Semaglutide does hold a weight management approval in the United States, under the separate name Wegovy. Dulaglutide holds no such approval at all: there is no second brand, no second label, and nothing in the approved document that describes it for weight.

03Written by us

Same class, and the boxed warning is the same

Both carry the boxed warning about the risk of thyroid C-cell tumors observed in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Repeated word for word across products of one class, that is a class warning rather than a statement about either product.

Below the box the lists run close: acute pancreatitis, hypoglycemia when combined with insulin or an insulin secretagogue, kidney injury, serious hypersensitivity. The Ozempic label adds diabetic retinopathy complications and an instruction that a pen must never be shared between patients.

04Written by us

Dosing is where the two documents actually diverge

Trulicity starts at 0.75 mg once weekly, may go to 1.5 mg after four weeks, and can be escalated further; it is supplied in single-dose pens of 0.75 mg, 1.5 mg, 3 mg and 4.5 mg. Ozempic starts at 0.25 mg once weekly, moves to 0.5 mg after four weeks, and can go to 1 mg and then 2 mg.

The numbers are not comparable between products: milligrams of dulaglutide and milligrams of semaglutide are different substances, and neither label converts one into the other.

A missed dose is handled differently, and this is a practical difference rather than a pharmacological one. Trulicity may be taken as soon as possible if at least 72 hours remain before the next scheduled dose. Ozempic may be taken within 5 days of the missed dose.

05Written by us

The reported common reactions are close but not identical

Both labels use a 5 percent threshold. Trulicity lists nausea, diarrhea, vomiting, abdominal pain and decreased appetite. Ozempic lists nausea, vomiting, diarrhea, abdominal pain and constipation.

The difference is at the end of each list: decreased appetite appears for one, constipation for the other. Both lists come from separate trials in different populations, so this is not a measured difference between the two products.

06Written by us

One is a biologic, the other is not

Trulicity is approved under a biologics license application rather than a new drug application, because dulaglutide is a protein. That is why there is no generic dulaglutide and will not be one: copies of biologics reach the market as biosimilars, under their own approvals.

Semaglutide is approved under a new drug application. Neither route says anything about how well either medication works; it determines what a copy of it would have to be called and how it would be approved.

07Written by us

Common questions

Is Trulicity or Ozempic approved for weight loss?: Neither. Both labels cover type 2 diabetes, with cardiovascular indications alongside. Semaglutide holds a separate weight management approval under the name Wegovy; dulaglutide holds no weight approval under any name.
Which one is stronger?: The labels do not compare them, and their doses cannot be compared either: 4.5 mg of dulaglutide and 2 mg of semaglutide are amounts of different substances. This page does not rank them.
What happens if a weekly dose is missed?: The two labels answer differently. Trulicity may be given as soon as possible provided at least 72 hours remain until the next scheduled dose. Ozempic may be given within 5 days of the missed dose. After those windows both labels direct the patient to skip and resume the usual schedule.
Is there a generic version of either?: Not for dulaglutide: it is a biologic, so copies would be biosimilars rather than generics, and none is approved. Semaglutide is a small molecule approved under a new drug application, but no approved generic semaglutide exists in the United States either.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Trulicity
Eli Lilly and Company. Label version 62, effective 16 June 2026.
Full label on DailyMed Approval record BLA125469
FDA prescribing information for Ozempic injection
A-S Medication Solutions. Label version 1, effective 30 July 2026.
Full label on DailyMed Approval record NDA209637

Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.